Immunophenotypic Analysis of Patients with CD56⁺ Acute Myeloid Leukemia.
- Author:
Rui GUO
1
;
An-Li SHEN
1
;
Yan WANG
1
;
Lu LIU
1
;
Jian-Fu ZHANG
1
;
Rong WANG
1
;
Jian-Yong LI
1
;
Yu-Jie WU
2
Author Information
- Publication Type:Journal Article
- MeSH: CD56 Antigen; metabolism; Flow Cytometry; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; classification; Prognosis
- From: Journal of Experimental Hematology 2015;23(5):1231-1234
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the immunophenotype characteristics of newly diagnosed patients with CD56⁺ acute myeloid leukemia (AML).
METHODSCombining with cytomorphology, four-color flow cytometry was used to analyze the immunophenotype of 342 AML patients with CD56⁺ or CD56⁻.
RESULTSIn 342 AML patients, the CD56⁺ expression was found in 83 AML patients who accounted for 24.27% and included 10 cases of M1, 45 cases of M2, 5 cases of M3, 6 cases of M6 and 17 cases of M5. The statistical analysis showed that there was statistical difference between CD56⁺ and CD11b⁺ patients (P < 0.05), but there was no statistical difference between CD56⁺ and HLA-DR, CD34, CD38, CD13, CD33, CD15, CD117, CD14, CD64, CD2, CD7, CD5, CD3, CD4, CD10, CD19, CD20, CD22 (P > 0.05).
CONCLUSIONAML with only CD56 positive always has poor prognosis, thus the prognosis of patients with CD56⁺ AML accompanied by other antigens still needs more research.
